Skip to main content
Mithra Pharmaceuticals S.A. logo

Mithra Pharmaceuticals S.A. — Investor Relations & Filings

Ticker · MITRA ISIN · BE0974283153 LEI · 5493002FDD273HTEKK14 BR Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2024-03-28 Legal Proceedings Report
Country BE Belgium
Listing BR MITRA

About Mithra Pharmaceuticals S.A.

https://www.mithra.com/

Mithra Pharmaceuticals S.A. is a biotech company dedicated to women's health. The company focuses on the development, manufacturing, and commercialization of differentiated drugs and complex therapeutic solutions. Its core areas of expertise include contraception, fertility, and menopause. Mithra aims to transform the women's health sector by providing innovative choices to support and improve the overall quality of life for women.

Recent filings

Filing Released Lang Actions
2024-03-28_Mithra_Press-release_Mithra-Updates-on-monetization-process_FR (1).pdf
Legal Proceedings Report Classification · 99% confidence The document is a press release dated March 28, 2024, titled "Mithra réalise une mise à jour sur son processus de monétisation en cours" (Mithra provides an update on its ongoing monetization process). It details significant corporate actions, including filing for judicial reorganization, requesting a court-supervised transfer for its CDMO unit, using proceeds from asset sales (Mayne Pharma shares) to repay debt, and implementing temporary unemployment measures. These are material, non-financial updates concerning corporate restructuring, legal proceedings, and financing/asset disposition, but they do not constitute a full Annual Report (10-K), a comprehensive Interim Report (IR), or a standard Earnings Release (ER) which focuses purely on financial figures. The content strongly aligns with announcements regarding significant corporate events, restructuring, and legal status changes. Since it is a detailed update on corporate strategy, restructuring, and legal maneuvers, it is best classified as a general Regulatory Filing (RNS) or potentially related to Legal Proceedings (LTR) or Capital/Financing (CAP). Given the broad nature covering multiple strategic and legal steps (reorganization, asset sale application, debt restructuring), and the fact that it is a direct announcement rather than a specific statutory form, RNS (Regulatory Filings - general regulatory announcements/fallback) is the most appropriate general category, although it contains elements of LTR and CAP. Since it is a direct, material announcement, RNS is chosen as the best fit among the provided options for a broad corporate update of this nature.
2024-03-28 French
2024-03-08_Mithra_Press-release_FY2023-Results_EN.pdf
Earnings Release Classification · 95% confidence The document is titled "Mithra reports full year 2023 financial results" and provides detailed financial highlights (revenues, sales, R&D expenses, REBITDA, cash position) and operational updates for the year ended December 31, 2023. It explicitly states the results were prepared in accordance with IFRS. This content structure—a comprehensive review of annual performance—is characteristic of an Annual Report or a detailed Earnings Release/Interim Report. Since it covers the full year and contains extensive financial detail, it aligns best with the scope of an Annual Report (10-K), although it is presented as a press release format. Given the options, and the comprehensive nature of the financial review for a full fiscal year, it is classified as an Annual Report (10-K) or, if it is the press release accompanying the 10-K, it is an Earnings Release (ER). However, the depth of financial data (e.g., detailed breakdown of out-licensing revenues, impairment losses, equity movements) suggests it is more than just the initial highlights of an ER. Since it is a full-year report, 10-K is the most appropriate regulatory equivalent for the content, even if the format is a press release. If the document were significantly shorter and only summarized key figures, ER would be better. Given the length and detail, I lean towards the comprehensive annual filing type, 10-K, as the content represents the core information found therein. If a specific 10-K filing was not made, this press release serves as the primary disclosure of annual results, making ER a strong secondary candidate. Given the context of financial reporting, I will select ER as it is the typical format for this type of detailed press release accompanying the filing. FY 2023
2024-03-08 English
2024-03-08_Mithra_Press-release_FY2023-Results_FR.pdf
Earnings Release Classification · 95% confidence The document is a comprehensive announcement of Mithra's annual financial results for the fiscal year 2023. It includes detailed financial highlights (revenue, R&D expenses, REBITDA, cash position, equity), operational highlights, and post-closing events. While it contains significant financial data and analysis, it is structured as a press release (indicated by the location/date header 'Liège, Belgique, 8 mars 2023 – 7 h 00 CET') rather than the full statutory Annual Report (10-K). Given the detailed financial breakdown and management commentary provided in the release, it fits the definition of an Earnings Release (ER) which covers the initial announcement of periodical financial results. FY 2023
2024-03-08 French
2024-03-05_Mithra_Press-release_change-of-management_EN.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the termination of the current CEO and the appointment of two new co-CEOs at Mithra Pharmaceuticals. This directly falls under the category of changes in senior management.
2024-03-05 English
2024-03-05_Mithra_Press-release_change-of-management_FR.pdf
Board/Management Information Classification · 100% confidence The document is a press release from Mithra announcing the termination of the CEO's management agreement and the appointment of two new co-CEOs. This falls directly under the category of announcements regarding changes in senior management.
2024-03-05 French
2024-03-05_Mithra_Press-Release_New-Secured-Bridge-Loan_EN.pdf
Capital/Financing Update Classification · 98% confidence The document is a press release dated March 5, 2024, announcing that Mithra has initiated a process to monetize its assets (sale of business/assets) and has secured a bridge loan facility to fund this process. It details the terms of the financing, the advisors appointed, and the expected liquidity runway. This content relates to significant corporate financing activities, asset restructuring, and strategic alternatives being explored. This aligns best with the 'Capital/Financing Update' category (CAP), as the primary focus is the securing of a bridge loan facility and the associated process to maximize stakeholder value through asset monetization, which is a form of capital/financing restructuring.
2024-03-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.